Hugh Gannon

Company: KSQ Therapeautics

Job title: Associate Director

Seminars:

Advancing Engineered TIL (eTIL®) Therapies for the Treatment of Solid Tumors 11:00 am

Exploring approaches to edit multiple T-cell targets for enhanced therapeutic efficacy against solid tumors Immune CRISPRomics® Platform discovered SOCS1 and Regnase-1 as top gene targets enhancing T-cell anti-tumor function Developing single and dual-edited eTIL® therapies with inactivation of SOCS1 and Regnase-1Read more

day: Conference Day Two